^
Association details:
| Biomarker: | EGFR exon 18 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLC
Excerpt:
...EGFR activating mutations in exon 18, 19 or 21were detected in tumor tissue or plasma....
Trial ID:
Source:
Title:
Study of Polyphenon E in Addition to Erlotinib in Advanced Non Small Cell Lung Cancer
Excerpt:
...Phase I: Response rate`Phase 1: Progression Free Survival`Phase 2: Progression Free Survival`Phase 2: Overall Survival`Phase 2: Correlation between level of EGFR expression on the original tumor tissue and the presence of EGFR mutations in exons 18, 19 and 21 in serum DNA and original tumor tissue with the treatment response and outcome.`...
Trial ID:
More C2 evidence
Source:
Title:
A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations
Excerpt:
...- Presence of mutation(s) in exon 18 through exon 21 of epidermal growth factor receptor (EGFR), (except T790M single mutation only)...
Trial ID:
Source:
Title:
A Single-arm Study to Evaluate the Efficacy of Intercalated Combination of Chemotherapy and Erlotinib as First-line Treatment for Patients With Non-Small-Cell Lung Cancer
Excerpt:
...EGFR mutation-positive (EGFR exon-18, exon-19 or exon-21); 5. ...
Trial ID:
Less C2 evidence
Source:
Title:
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study
Published date:
04/05/2022
Excerpt:
We retrospectively evaluated survival characteristics of 125 patients with EGFR exon 18 and exon 20 mutated NSCLC who received erlotinib or afatinib as first line treatment between 2012 and 2021 from 34 oncology centres….PFS of exon 18 mutated arm was 7.0 months, exon 20 mutated arm was 4.3 months, and complex mutation positive group was 17.3 months, and this was statistically significant (p = 0.036).
DOI:
https://doi.org/10.1007/s00432-022-03984-5
Source:
Title:
Real Life Comparison of Afatinib and Erlotinib in Non-small Cell Lung Cancer With Rare EGFR Exon 18 and Exon 20 Mutations: a Turkish Oncology Group (TOG) Study.
Published date:
12/10/2021
Excerpt:
We retrospectively evaluated survival characteristics of 125 patients with EGFR exon 18 and exon 20 mutated NSCLC who received erlotinib or afatinib….OS of all patients was 21.4 months (95%CI: 16.1-26.6), while PFS was 7.2 months (95%CI: 5.1-9.3). When PFS and OS were compared according to the type of TKI used, PFS was 8.0 months (95%CI: 4.7-11.3) in the erlotinib arm and 7.0 months (95%CI: 4.4-9.6) in the afatinib arm.
DOI:
10.21203/rs.3.rs-1125056/v1
